Optison

(Albumin Human)

PreclinicalSmall molecule

GGE Healthcare

Optison is one of 42 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukemiaRecruiting

Acute Lymphoblastic LeukemiaPreclinical

Recruiting

Competition

Competitive Landscape

163 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

75 2

Adriamycin

Pfizer

Phase 3

40 3

Oncaspar

SServier

Phase 3

48 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

40 5

Elspar

DDutch Childhood Oncology Group

Phase 3

45 6

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 7

Fludara

Sanofi

Phase 3

15 8

Iclusig

Takeda

Phase 3

12 9

Cellcept

Neoral

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Effect of Early Administration of Albumin 20% Versus Crystalloid

Recruiting·EEgymedicalpedia·N/A·NCT06370078·46 enrolled

Prospective1 trial

The Acute Burn ResUscitation Multicenter Prospective Trial

Unknown status·AAmerican Burn Association·N/A·NCT04356859·400 enrolled

MPA1 trial

Compare the Diuretic Effect With Furosemide vs Furosemide and Albumin Combined in Cirrhotic Patients

Terminated·RRush University Medical Center·Phase 4·NCT04216784·21 enrolled

Pneumonia1 trial

Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.

Terminated·JJordi Carratala·Phase 3·NCT04071041·39 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 31, 1997

OPTISON

NDA NDA020899

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Albumin Human. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albumin Human compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albumin Human. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020899). U.S. Food & Drug Administration.
[5]
SEC EDGAR — GE Healthcare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGE Healthcare

Optison

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Prospective1 trial

MPA1 trial

Pneumonia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News